Mooney R D, Crnko-Hoppenjans T A, Ke M, Bennett-Clarke C A, Lane R D, Chiaia N L, Rhoades R W
Department of Anatomy and Neurobiology, Medical College of Ohio, Toledo 43614, USA.
J Comp Neurol. 1998 Mar 30;393(1):84-92.
A previous study from this laboratory showed that sprouting of serotoninergic axons in the hamster's superior colliculus (SC) induced by a single subcutaneous injection of 5,7-dihydroxytryptamine (5,7-DHT) at birth (postnatal day 0; P-0) resulted in an abnormal terminal distribution of the uncrossed retinotectal projection. The present study provided further evidence to support the role of increased 5-HT levels within the SC in this phenomenon. Slow-release polymer (ELVAX) chips impregnated with serotonin (5-HT) were placed over the SC on either P-1 or P-3, and retinotectal projections were assessed via anterograde transport of horseradish peroxidase when animals reached P > 18. Analysis of ELVAX chips indicated that they released 5-HT in amounts of > or = 1 pmole/hour for at least 12 days. Assessment of the SC of treated hamsters indicated significantly elevated 5-HT concentrations as late as P-12, but not on P-16. Implantation of 5-HT chips, but not control chips, resulted in abnormalities in the uncrossed retinotectal projection similar to those observed in the 5,7-DHT-treated animals. The patches that normally develop in the rostral part of the stratum opticum were not present, and uncrossed axons were distributed densely in this layer and in the lower portion of the stratum griseum superficiale throughout the rostrocaudal and mediolateral extents of the SC. Quantitative analysis of these changes indicated significant differences between the organization of the uncrossed retinotectal projections of 5-HT-treated animals vs. either blank-implant treated or completely untreated animals but not between 5-HT-treated hamsters and animals that received neonatal 5,7-DHT injections. All of these results support the conclusion that increased SC concentrations of 5-HT altered retinotectal development.
本实验室之前的一项研究表明,出生时(出生后第0天;P-0)单次皮下注射5,7-二羟基色胺(5,7-DHT)诱导仓鼠上丘(SC)中5-羟色胺能轴突发芽,导致未交叉的视网膜顶盖投射的终末分布异常。本研究提供了进一步的证据来支持SC内5-羟色胺水平升高在此现象中的作用。在P-1或P-3时,将浸渍有5-羟色胺(5-HT)的缓释聚合物(ELVAX)芯片置于SC上方,当动物达到P>18时,通过辣根过氧化物酶的顺行运输评估视网膜顶盖投射。对ELVAX芯片的分析表明,它们至少在12天内以≥1皮摩尔/小时的量释放5-HT。对接受治疗的仓鼠的SC评估表明,直到P-12时5-HT浓度显著升高,但在P-16时没有升高。植入5-HT芯片而非对照芯片,导致未交叉的视网膜顶盖投射出现异常,类似于在5,7-DHT处理的动物中观察到的异常。通常在视层前部形成的斑块不存在,未交叉的轴突密集分布在该层以及整个SC的前后和内外范围的浅灰色层下部。对这些变化的定量分析表明,5-HT处理动物的未交叉视网膜顶盖投射的组织与空白植入处理或完全未处理动物之间存在显著差异,但5-HT处理的仓鼠与接受新生期5,7-DHT注射的动物之间没有差异。所有这些结果支持这样的结论,即SC中5-HT浓度升高改变了视网膜顶盖的发育。